- Home
- ERAS vs SGHC Comparison
ERAS vs SGHC Comparison
Compare ERAS & SGHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | SGHC |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ERAS | SGHC |
|---|---|---|
| Price | $9.95 | $13.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $14.25 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 9.1M | 3.2M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.52% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.09 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | ★ N/A | $20.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $8.08 |
| 52 Week High | $24.28 | $14.38 |
Technical Indicators
Market Signals| Indicator | ERAS | SGHC |
|---|---|---|
| Relative Strength Index (RSI) | 33.19 | 72.07 |
| Support Level | $2.07 | $10.18 |
| Resistance Level | $17.17 | $14.38 |
| Average True Range (ATR) | 1.74 | 0.57 |
| MACD | -1.29 | 0.10 |
| Stochastic Oscillator | 8.02 | 91.03 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About SGHC Super Group (SGHC) Limited
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.